Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

ALK-Abello A/S stock

ALK B.CO
DK0060027142
A0H0J1

Price

160.20 DKK
Today +/-
+0.42 DKK
Today %
+1.95 %

ALK-Abello A/S stock price

DKK
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the ALK-Abello A/S stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the ALK-Abello A/S stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the ALK-Abello A/S stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze ALK-Abello A/S's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

ALK-Abello A/S Stock Price History

DateALK-Abello A/S Price
12/27/2024160.20 DKK
12/23/2024157.10 DKK
12/20/2024161.30 DKK
12/19/2024154.80 DKK
12/18/2024161.50 DKK
12/17/2024153.00 DKK
12/16/2024154.90 DKK
12/13/2024153.10 DKK
12/12/2024155.00 DKK
12/11/2024155.50 DKK
12/10/2024157.80 DKK
12/9/2024159.80 DKK
12/6/2024161.60 DKK
12/5/2024163.10 DKK
12/4/2024164.40 DKK
12/3/2024162.30 DKK
12/2/2024166.40 DKK

ALK-Abello A/S Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ALK-Abello A/S, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ALK-Abello A/S from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ALK-Abello A/S’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ALK-Abello A/S. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ALK-Abello A/S’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ALK-Abello A/S’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ALK-Abello A/S’s growth potential.

ALK-Abello A/S Revenue, EBIT and net profit per share

DateALK-Abello A/S RevenueALK-Abello A/S EBITALK-Abello A/S Net Income
2029e9.21 B DKK2.52 B DKK1.6 B DKK
2028e8.38 B DKK2.24 B DKK1.51 B DKK
2027e7.76 B DKK1.97 B DKK1.31 B DKK
2026e7.26 B DKK1.84 B DKK1.35 B DKK
2025e6.49 B DKK1.63 B DKK1.16 B DKK
2024e5.76 B DKK1.19 B DKK823.6 M DKK
20234.82 B DKK666 M DKK486 M DKK
20224.51 B DKK470 M DKK335 M DKK
20213.92 B DKK291 M DKK219 M DKK
20203.49 B DKK151 M DKK25 M DKK
20193.27 B DKK1 M DKK-50 M DKK
20182.92 B DKK-96 M DKK-170 M DKK
20172.91 B DKK-80 M DKK-158 M DKK
20163.01 B DKK479 M DKK270 M DKK
20152.57 B DKK294 M DKK344 M DKK

ALK-Abello A/S Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B DKK)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B DKK)NET INCOME (B DKK)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
2.573.012.912.923.273.493.924.514.825.766.497.267.768.389.21
-16.97-3.160.1712.326.6312.1715.196.9419.3012.7211.956.807.9810.01
67.4666.4656.4356.0257.7958.0961.1861.8762.9152.7446.7941.7939.1336.2432.94
1.7321.641.631.892.032.42.793.04000000
0.340.27-0.16-0.17-0.050.030.220.340.490.821.161.351.311.511.6
--21.51-158.527.59-70.59-150.00776.0052.9745.0769.3440.8316.48-2.8915.335.56
9.84198.27198.43217.33217.77219.89220.99221.37221.28000000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The ALK-Abello A/S Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the ALK-Abello A/S is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M DKK)RECEIVABLES (M DKK)OTHER REC. (M DKK)INVENTORIES (B DKK)OTHER CURRENT LIAB. (M DKK)CURRENT ASSETS (B DKK)TANGIBLE ASSETS (B DKK)LONG-T. INVEST. (M DKK)LONG-T. REC. (M DKK)INTANGIBLE ASSETS (M DKK)GOODWILL (M DKK)OTHER NON-CURRENT ASSETS (M DKK)NON-CURRENT ASSETS (B DKK)TOTAL ASSETS (B DKK)LIABILITIESCOMMON STOCK (M DKK)ADDITIONAL PAID-IN CAPITAL (M DKK)RETAINED EARNINGS (B DKK)OTHER EQUITY (M DKK)UNREAL. GAINS/LOSSES (M DKK)EQUITY (B DKK)LIABILITIES (M DKK)PROVISIONS (M DKK)OTHER SHORT-TERM LIAB. (M DKK)SHORT-TERM DEBTS (M DKK)LONG-TERM DEBT PORTION (M DKK)SHORT-TERM REC. (B DKK)LONG-T. LIAB. (M DKK)DEFERRED TAXES (M DKK)OTHER LIAB. (M DKK)LONG-T. LIABILITIES (B DKK)DEBT (B DKK)TOTAL CAPITAL (B DKK)
201520162017201820192020202120222023
                 
608840711396316298194221474
273295326328407544583764816
109114163199258140108124108
0.520.680.880.991.061.091.21.31.42
26268083211265314239147
1.541.952.1622.252.342.42.652.97
1.571.631.581.581.741.71.812.022.18
8879460000
0000160198201193198
336342291260221172165182212
423422461465461452457460459
378449466548620697790810708
2.722.852.82.873.253.223.433.663.76
4.254.84.964.875.55.565.836.316.73
                 
101101111111111111111111111
000000000
2.582.753.273.113.083.173.413.864.35
1422-87-42-19-125-4120-18
000000000
2.72.883.293.183.183.153.483.994.45
811321211358174115131128
2180000485618625644
303658528574804420371376216
000000000
3171717174950281267326
0.920.810.670.730.931.031.391.41.31
327756740725941893429429439
100124216147143144
209237241229297345535488522
0.641.1210.961.391.380.970.920.97
1.561.921.671.692.322.412.352.322.28
4.254.84.964.875.55.565.836.316.73
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of ALK-Abello A/S provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand ALK-Abello A/S's financial health and stability.

Assets

ALK-Abello A/S's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that ALK-Abello A/S must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of ALK-Abello A/S after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into ALK-Abello A/S's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M DKK)DEPRECIATION (M DKK)DEFERRED TAXES (M DKK)CHANGES IN WORKING CAPITAL (M DKK)NON-CASH ITEM (M DKK)PAID INTEREST (M DKK)PAID TAXES (M DKK)NET CASH FLOW FROM OPERATING ACTIVITIES (M DKK)CAPITAL EXPENDITURES (M DKK)CASH FLOW FROM INVESTING ACTIVITIES (M DKK)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M DKK)INTEREST INCOME AND EXPENSES (M DKK)NET DEBT CHANGE (M DKK)NET CHANGE IN EQUITY (M DKK)CASH FLOW FROM FINANCING ACTIVITIES (M DKK)CASH FLOW FROM OTHER FINANCING ACTIVITIES (DKK)TOTAL DIVIDENDS PAID (M DKK)NET CHANGE IN CASH FLOW (M DKK)FREE CASH FLOW (M DKK)SHARE-BASED COMPENSATION (M DKK)
201520162017201820192020202120222023
344270-158-170-5025219335486
159163333232255245242238245
000000000
-233-242-649-231-106-168-128-313-263
-87214877433199135156199
00000023140
14718634915484141007860
183405-387-95132301468416667
-199-225-267-178-167-222-263-353-379
-165-204-358-199-157-245-266-351-375
3421-91-2110-23-324
000000000
320130-17-18-44-49-270-73-11
27-42686-10-13-13-4131-20
29839620-28-57-62-311-42-31
-------72.00-11.00-
-49-49-49000000
319232-129-315-80-18-10427253
-16180-654-273-357920563288
000000000

ALK-Abello A/S stock margins

The ALK-Abello A/S margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ALK-Abello A/S. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ALK-Abello A/S.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ALK-Abello A/S's sales revenue. A higher gross margin percentage indicates that the ALK-Abello A/S retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ALK-Abello A/S's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ALK-Abello A/S's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ALK-Abello A/S's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ALK-Abello A/S. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ALK-Abello A/S's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ALK-Abello A/S Margin History

ALK-Abello A/S Gross marginALK-Abello A/S Profit marginALK-Abello A/S EBIT marginALK-Abello A/S Profit margin
2029e62.91 %27.34 %17.33 %
2028e62.91 %26.79 %18.06 %
2027e62.91 %25.4 %16.91 %
2026e62.91 %25.32 %18.59 %
2025e62.91 %25.05 %17.88 %
2024e62.91 %20.71 %14.31 %
202362.91 %13.81 %10.07 %
202261.87 %10.42 %7.43 %
202161.18 %7.43 %5.59 %
202058.09 %4.33 %0.72 %
201957.79 %0.03 %-1.53 %
201856.02 %-3.29 %-5.83 %
201756.43 %-2.75 %-5.43 %
201666.46 %15.94 %8.99 %
201567.46 %11.44 %13.39 %

ALK-Abello A/S Stock Sales Revenue, EBIT, Earnings per Share

The ALK-Abello A/S earnings per share therefore indicates how much revenue ALK-Abello A/S has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ALK-Abello A/S earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ALK-Abello A/S's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ALK-Abello A/S’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ALK-Abello A/S's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ALK-Abello A/S Revenue, EBIT and net profit per share

DateALK-Abello A/S Sales per ShareALK-Abello A/S EBIT per shareALK-Abello A/S Earnings per Share
2029e45.82 DKK0 DKK7.94 DKK
2028e41.65 DKK0 DKK7.52 DKK
2027e38.57 DKK0 DKK6.52 DKK
2026e36.12 DKK0 DKK6.72 DKK
2025e32.26 DKK0 DKK5.77 DKK
2024e28.62 DKK0 DKK4.1 DKK
202321.8 DKK3.01 DKK2.2 DKK
202220.38 DKK2.12 DKK1.51 DKK
202117.72 DKK1.32 DKK0.99 DKK
202015.88 DKK0.69 DKK0.11 DKK
201915.03 DKK0 DKK-0.23 DKK
201813.41 DKK-0.44 DKK-0.78 DKK
201714.67 DKK-0.4 DKK-0.8 DKK
201615.16 DKK2.42 DKK1.36 DKK
2015260.97 DKK29.87 DKK34.95 DKK

ALK-Abello A/S business model

ALK-Abello A/S is a Danish company specializing in the production of allergy-based products and therapies. It was founded in 1923 by Dr. H. C. Harald Petersen and is headquartered in Hørsholm, Denmark. The company's history began with Dr. Petersen's discovery that allergens could be administered to trigger an immune reaction in a control system. He developed a therapy for hay fever using pollen extracts from grasses, flowers, and trees to desensitize the immune system to these allergens. In 1940, ALK introduced the first specific immunotherapy (SIT) for protection against pollen allergies. ALK-Abello A/S is a leading provider of allergen-based therapeutics and diagnostic tests for allergic diseases. The company offers two main products: allergen immunotherapies and diagnostic tests for allergic diseases. These products are offered in 28 countries worldwide, and the company is the largest provider of allergen-based therapeutics in Europe. ALK-Abello A/S operates three main divisions: allergen immunotherapies, diagnostic products, and other specialty products. The allergen immunotherapies are based on allergen extracts and aim to train the immune system to tolerate allergens by administering a small amount that is enough to trigger an immune response but not cause an allergic reaction. These therapies are used for various allergic diseases, including hay fever, asthma, and allergic skin conditions. The diagnostic products of ALK-Abello A/S are used for the diagnosis of allergic diseases. There are different types of diagnostic tests, including skin tests, in vitro diagnostic tests, and specific IgE tests (blood tests). Other specialty products of ALK-Abello A/S include products for the treatment of specific allergies or diseases related to allergies. Examples include adrenaline auto-injectors for the treatment of anaphylactic shock and nasal sprays for the treatment of hay fever. In summary, ALK-Abello A/S is a leading provider of allergy products and therapies, with a long history in the development of allergen-based therapeutics. The company operates three main divisions and offers a wide range of products that can be used for the diagnosis and treatment of allergic diseases. ALK-Abello A/S is one of the most popular companies on Eulerpool.com.

ALK-Abello A/S SWOT Analysis

Strengths

ALK-Abello A/S has several strengths that contribute to its success. Firstly, the company has a strong research and development team, allowing them to stay at the forefront of developing new allergy treatments. This enables them to offer innovative and effective solutions to their customers. Additionally, ALK-Abello has a wide range of products in its portfolio, catering to various allergies and respiratory diseases, which gives them a competitive edge in the market.

Furthermore, the company has established a strong brand presence and enjoys a loyal customer base. It has a long-standing history of providing high-quality products, which has helped build trust among its target audience. ALK-Abello also benefits from a global presence, with operations and distribution networks in multiple countries, enabling them to reach a larger customer base.

Weaknesses

Despite its strengths, ALK-Abello A/S also has some weaknesses that could hinder its growth. One significant weakness is its dependence on a limited number of products for a major portion of its revenue. This leaves the company vulnerable to changes in consumer preferences or regulatory restrictions in specific markets. Additionally, ALK-Abello faces intense competition from both established pharmaceutical companies and emerging players in the allergy treatment market.

Another weakness is the company's limited geographic presence in certain regions. This restricts their reach and market share in those areas, potentially missing out on potential growth opportunities.

Opportunities

ALK-Abello A/S has opportunities that can be leveraged for future growth. The increasing prevalence of allergies and respiratory diseases worldwide presents a vast market for the company. By expanding its product offerings and investing in research, ALK-Abello can tap into this growing demand and capture a larger market share.

Furthermore, there is a rising trend towards personalized medicine and targeted therapies. ALK-Abello can capitalize on this trend by developing customized immunotherapy solutions that cater to individual patient needs. This would not only differentiate them from competitors but also provide better treatment outcomes for patients.

Threats

ALK-Abello A/S faces several threats that need to be addressed. The regulatory environment in the pharmaceutical industry can pose challenges, with stringent requirements for drug approvals and pricing regulations. Compliance with these regulations and ongoing changes could impact the company's operations and profitability.

The company also faces the risk of patent expirations, which could lead to the entry of generic competitors offering similar products at lower prices. Additionally, evolving market trends and shifts in consumer preferences can disrupt demand for certain product categories, requiring ALK-Abello to adapt and innovate frequently.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

ALK-Abello A/S Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

ALK-Abello A/S historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

ALK-Abello A/S shares outstanding

The number of shares was ALK-Abello A/S in 2023 — This indicates how many shares 221.276 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ALK-Abello A/S earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ALK-Abello A/S's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ALK-Abello A/S’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ALK-Abello A/S's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ALK-Abello A/S stock splits

In ALK-Abello A/S's history, there have been no stock splits.

ALK-Abello A/S dividend history and estimates

In 2023, ALK-Abello A/S paid a dividend amounting to 0 DKK. Dividend means that ALK-Abello A/S distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for ALK-Abello A/S provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify ALK-Abello A/S’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating ALK-Abello A/S's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

ALK-Abello A/S Dividend History

DateALK-Abello A/S Dividend
2029e17.49 DKK
2028e16.56 DKK
2027e14.32 DKK
2026e14.85 DKK
2025e12.69 DKK
2024e8.91 DKK
20175 DKK
20165 DKK
20155 DKK

ALK-Abello A/S dividend payout ratio

In 2023, ALK-Abello A/S had a payout ratio of 225.59%. The payout ratio indicates the percentage of the company's profits that ALK-Abello A/S distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for ALK-Abello A/S represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for ALK-Abello A/S could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate ALK-Abello A/S's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

ALK-Abello A/S Payout Ratio History

DateALK-Abello A/S Payout ratio
2029e220.28 %
2028e220.22 %
2027e219.56 %
2026e221.07 %
2025e220.02 %
2024e217.6 %
2023225.59 %
2022216.87 %
2021210.34 %
2020249.55 %
2019190.74 %
2018190.74 %
2017-627.93 %
2016367.16 %
201514.31 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for ALK-Abello A/S.

ALK-Abello A/S latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.62 DKK0.9 DKK (45.63 %)2024 Q2
3/31/20241.03 DKK1.1 DKK (6.8 %)2024 Q1
3/31/20230.94 DKK0.7 DKK (-25.32 %)2023 Q1
12/31/20220.37 DKK0.35 DKK (-4.27 %)2022 Q4
9/30/20220.16 DKK0.23 DKK (39.56 %)2022 Q3
6/30/20220.06 DKK0.19 DKK (196.41 %)2022 Q2
3/31/20220.67 DKK0.74 DKK (10.1 %)2022 Q1
12/31/20210.2 DKK0.35 DKK (71.63 %)2021 Q4
9/30/20210.04 DKK0.17 DKK (279.46 %)2021 Q3
6/30/2021-0.02 DKK-0.1 DKK (-389.69 %)2021 Q2
1
2
3
4
5
...
7

Eulerpool ESG Scorecard© for the ALK-Abello A/S stock

Eulerpool World ESG Rating (EESG©)

83/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

51

Environment

Scope 1 - Direct Emissions
4,924
Scope 2 - Indirect emissions from purchased energy
5,669
Scope 3 - Indirect emissions within the value chain
70,475
Total CO₂ emissions
10,593
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees63
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

ALK-Abello A/S shareholders

%
Name
Stocks
Change
Date
34.56247 % Lundbeckfond Invest69,496,540012/31/2023
5.58315 % ATP11,226,329-235,00012/31/2023
1.94027 % The Vanguard Group, Inc.3,901,39520,4129/30/2024
1.78002 % M&G Investment Management Ltd.3,579,182-31,6378/31/2024
1.60381 % Norges Bank Investment Management (NBIM)3,224,861-241,1206/30/2024
1.25437 % Nordea Investment Management AB (Denmark)2,522,23638,5468/31/2024
1.15284 % La Financi¿re de l'Echiquier2,318,06608/31/2024
0.99475 % Dimensional Fund Advisors, L.P.2,000,196258/31/2024
0.99135 % BI Asset Management Fondsm¿glerselskab A/S1,993,34919,6639/30/2024
0.93480 % BlackRock Institutional Trust Company, N.A.1,879,64717,8659/30/2024
1
2
3
4
5
...
10

ALK-Abello A/S Executives and Management Board

Mr. Soeren Niegel

(53)
ALK-Abello A/S Executive Vice President - Commercial Operations
Compensation 6.51 M DKK

Dr. Henriette Mersebach

(53)
ALK-Abello A/S Executive Vice President - Research and Development
Compensation 4.88 M DKK

Mr. Claus Solje

(52)
ALK-Abello A/S Executive Vice President, Chief Financial Officer
Compensation 4.11 M DKK

Mr. Peter Halling

(47)
ALK-Abello A/S President, Chief Executive Officer
Compensation 2 M DKK

Mr. Anders Hedegaard

(64)
ALK-Abello A/S Independent Chairman of the Board
Compensation 1.33 M DKK
1
2
3
4

Most common questions regarding ALK-Abello A/S

What values and corporate philosophy does ALK-Abello A/S represent?

ALK-Abello A/S is a prominent pharmaceutical company focused on allergy immunotherapy. The company's values revolve around providing effective, patient-centric solutions to allergy-related conditions. With a strong commitment to research and development, ALK-Abello A/S strives to constantly innovate and improve allergy treatments. The company's corporate philosophy emphasizes scientific expertise, quality, and safety in all aspects of their operations. ALK-Abello A/S aims to enhance the quality of life for individuals suffering from allergies through their dedication to excellence and continued advancements in allergy immunotherapy.

In which countries and regions is ALK-Abello A/S primarily present?

ALK-Abello A/S is primarily present in several countries and regions around the world. The company has a strong presence in Europe, with significant operations in Denmark, where it is headquartered, as well as in other European countries like Germany, France, and the United Kingdom. ALK-Abello A/S also has a significant presence in North America, with operations in the United States and Canada. Additionally, the company has expanded its presence in Asia, with operations in countries such as China and Japan. Overall, ALK-Abello A/S has a global footprint that spans multiple regions, allowing it to serve a diverse range of markets and customers.

What significant milestones has the company ALK-Abello A/S achieved?

ALK-Abello A/S, a renowned pharmaceutical company, has attained several significant milestones over the years. The company has successfully developed and commercialized various immunotherapy products, focusing on the treatment of severe allergies. Notably, ALK-Abello A/S achieved regulatory approvals for its flagship product, GRAZAX®, in multiple countries, revolutionizing the field of allergy treatment. Furthermore, the company has expanded its global presence by establishing subsidiaries and partnerships worldwide, allowing them to reach a wider patient base. ALK-Abello A/S continues to innovate and conduct groundbreaking research, constantly striving to enhance the lives of individuals affected by allergies.

What is the history and background of the company ALK-Abello A/S?

ALK-Abello A/S, founded in 1923, is a leading global pharmaceutical company specializing in allergy immunotherapy. With a rich history spanning nearly a century, ALK-Abello has become synonymous with innovation and excellence in the field of allergen immunotherapy. The company is committed to advancing and constantly improving the treatment of respiratory allergies, such as allergic rhinitis and allergic asthma. ALK-Abello focuses on developing and producing a wide range of high-quality, patient-friendly allergy vaccines, including subcutaneous, sublingual, and tablet-based treatments. This Danish company is dedicated to tackling the burden of allergies worldwide, improving the quality of life for allergy sufferers through its extensive portfolio of products and research efforts.

Who are the main competitors of ALK-Abello A/S in the market?

ALK-Abello A/S, a leading pharmaceutical company specializing in allergy immunotherapy, faces competition in the market from several key players. Some of the main competitors of ALK-Abello A/S include companies like Stallergenes Greer, Allergy Therapeutics, Circassia Pharmaceuticals, and Merck KGaA. These companies also operate in the field of allergy immunotherapy and offer a range of products and treatments. ALK-Abello A/S engages in rigorous research and innovation to maintain its competitive edge and provide effective solutions to individuals suffering from allergies.

In which industries is ALK-Abello A/S primarily active?

ALK-Abello A/S is primarily active in the pharmaceutical industry.

What is the business model of ALK-Abello A/S?

The business model of ALK-Abello A/S revolves around the development, manufacturing, and sale of allergy immunotherapy treatments. As a leading pharmaceutical company, ALK-Abello focuses on providing allergy sufferers with effective, patient-tailored solutions. They have a strong portfolio of products, including subcutaneous and sublingual allergy immunotherapy vaccines, which help build immunity and alleviate allergic symptoms. ALK-Abello A/S combines research and innovation to deliver high-quality and safe allergy treatments, helping individuals improve their quality of life. Their commitment to addressing the unmet needs of allergy patients has made them a trusted name in the industry.

What is the P/E ratio of ALK-Abello A/S 2024?

The ALK-Abello A/S P/E ratio is 43.04.

What is the P/S ratio of ALK-Abello A/S 2024?

The ALK-Abello A/S P/S ratio is 6.16.

What is the Quality Investing of ALK-Abello A/S?

The Quality Investing for ALK-Abello A/S is 4/10.

What is the revenue of ALK-Abello A/S 2024?

The expected ALK-Abello A/S revenue is 5.76 B DKK.

How high is the profit of ALK-Abello A/S 2024?

The expected ALK-Abello A/S profit is 823.6 M DKK.

What is the business model of ALK-Abello A/S

ALK-Abello A/S is a Danish pharmaceutical company specialized in allergic diseases since its founding in 1923. With its innovative research results and comprehensive portfolio of high-quality allergological products, it is one of the leading companies in the industry. ALK-Abello is divided into various business areas, all specialized in the manufacturing and distribution of products for the diagnosis and treatment of different allergic diseases. These include immunotherapy, allergy diagnostics, plant breeding, and sales & marketing. In the field of immunotherapy, ALK-Abello focuses on the development, manufacturing, and marketing of allergen vaccines. These are offered in the form of injection solutions or sublingual tablets and serve for the long-term treatment of allergic symptoms. ALK-Abello's products are known for their high efficacy, safety, and compatibility and are distributed in more than 30 countries worldwide. The allergy diagnostics area encompasses a wide range of diagnostic tests that can be used for the identification of allergies and determination of allergen doses. This includes in vitro tests such as blood tests or the RAST method, as well as in vivo tests like the prick test. ALK-Abello is a leader in the development of diagnostics and offers both standard and customized test systems. In the field of plant breeding, ALK-Abello specializes in breeding natural allergen sources. The goal is to produce allergens of suitable quality and concentration for the manufacturing of allergen vaccines. The company has several specialized plantations in different countries and is also involved in researching alternative allergen sources such as mold or house dust mites. Finally, the sales and marketing team of ALK-Abello is crucial for the company's business model. It ensures that ALK-Abello's products are available worldwide, advises doctors and patients on treatment options, and is responsible for communication with regulatory authorities. Overall, the business model of ALK-Abello is based on a holistic approach that combines research, development, production, and marketing. The company focuses on the needs of allergy sufferers and works closely with specialist doctors and research institutions worldwide. With its high-quality products and experienced team of specialists, ALK-Abello is well-equipped to continue playing an important role in the fight against allergic diseases.

What is the ALK-Abello A/S dividend?

ALK-Abello A/S pays a dividend of 0 DKK distributed over payouts per year.

How often does ALK-Abello A/S pay dividends?

The dividend cannot currently be calculated for ALK-Abello A/S or the company does not pay out a dividend.

What is the ALK-Abello A/S ISIN?

The ISIN of ALK-Abello A/S is DK0060027142.

What is the ALK-Abello A/S WKN?

The WKN of ALK-Abello A/S is A0H0J1.

What is the ALK-Abello A/S ticker?

The ticker of ALK-Abello A/S is ALK B.CO.

How much dividend does ALK-Abello A/S pay?

Over the past 12 months, ALK-Abello A/S paid a dividend of 5 DKK . This corresponds to a dividend yield of about 3.12 %. For the coming 12 months, ALK-Abello A/S is expected to pay a dividend of 12.69 DKK.

What is the dividend yield of ALK-Abello A/S?

The current dividend yield of ALK-Abello A/S is 3.12 %.

When does ALK-Abello A/S pay dividends?

ALK-Abello A/S pays a quarterly dividend. This is distributed in the months of April, April, April, April.

How secure is the dividend of ALK-Abello A/S?

ALK-Abello A/S paid dividends every year for the past 6 years.

What is the dividend of ALK-Abello A/S?

For the upcoming 12 months, dividends amounting to 12.69 DKK are expected. This corresponds to a dividend yield of 7.92 %.

In which sector is ALK-Abello A/S located?

ALK-Abello A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von ALK-Abello A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ALK-Abello A/S from 3/20/2017 amounting to 5 DKK, you needed to have the stock in your portfolio before the ex-date on 3/16/2017.

When did ALK-Abello A/S pay the last dividend?

The last dividend was paid out on 3/20/2017.

What was the dividend of ALK-Abello A/S in the year 2023?

In the year 2023, ALK-Abello A/S distributed 0 DKK as dividends.

In which currency does ALK-Abello A/S pay out the dividend?

The dividends of ALK-Abello A/S are distributed in DKK.

All fundamentals about ALK-Abello A/S

Our stock analysis for ALK-Abello A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ALK-Abello A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.